Tuesday, July 10, 2012

Chinese and Australian Patents Allowed for 22nd Century's NBB Nicotine Biosynthesis Gene - MarketWatch

 22nd Century expects the NBB gene technology to play an important role in reducing the harm caused by smoking. The company announced on April 10, 2012 that it will file applications with the U.S. Food and Drug Administration (FDA) for two types of modified risk cigarettes in accordance with the FDA's Modified Risk Tobacco Product Applications Draft Guidance. A presentation titled, Effect of Smoking Low Tar-to-Nicotine Ratio Cigarettes on Smoke Exposure, will be given by 22nd Century Group at the 66th Tobacco Science Research Conference being held in Concord, North Carolina on September 9-12. The presentation will summarize 22nd Century's planned exposure study on one of its two modified-risk cigarette candidates.

Chinese and Australian Patents Allowed for 22nd Century's NBB Nicotine Biosynthesis Gene - MarketWatch

No comments:

Post a Comment

There was an error in this gadget